The score is held down primarily by weak financial quality—ongoing net losses, higher leverage, and negative free cash flow—despite respectable gross/operating margins. Technicals provide some support via improving short-term momentum, but the longer-term downtrend and loss-driven valuation profile limit the overall rating.
Positive Factors
Strong gross and operating margins
Sizable gross (~47%) and operating margins (EBIT ~15%, EBITDA ~37%) provide durable cash margins that help absorb commodity volatility. Sustained mid/high margins support ongoing capex and operating needs, improving resilience and the company’s ability to sustain operations through cycles.
Positive operating cash generation
Positive operating cash flow (~7.0M TTM) shows the core business generates cash despite losses. Persistent OCF reduces reliance on external funding, helps fund working capital and maintenance capex, and enhances medium-term operational sustainability if the trend holds.
Positive equity buffer
A positive equity base (~34.5M TTM) provides a meaningful balance-sheet buffer against ongoing losses and cyclical shocks. This equity cushion improves the company’s ability to access financing, absorb write-downs, and pursue necessary investment without immediate solvent stress.
Negative Factors
Rising leverage
Total debt rising to ~83.0M with debt/equity ~2.41 (from ~1.49) materially increases leverage. Higher indebtedness raises interest and refinancing risk, constrains strategic flexibility, and heightens vulnerability to lower cash flows or commodity downturns over the next several quarters.
Persistent net losses and negative FCF
A net margin near -30% and negative free cash flow (~-5.2M TTM) indicate core profitability is not converting into surplus cash. Continued cash burn depletes reserves, weakens financial flexibility, and likely forces external financing or asset sales, impairing long-term strategic options.
Revenue decline and earnings volatility
TTM revenue decline (~-6.9%) and multi-period weakness (RevenueGrowth -23.47%) signal choppy demand or production inconsistency. Persistent top-line erosion undermines scale economics, makes earnings less predictable, and complicates deleveraging and internally funding growth initiatives.
Modiin Pu (MDIN) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪25.96M
Dividend YieldN/A
Average Volume (3M)28.00K
Price to Earnings (P/E)―
Beta (1Y)0.81
Revenue Growth-23.47%
EPS Growth28.77%
CountryIL
Employees8
SectorEnergy
Sector Strength52
IndustryOil & Gas Exploration & Production
Share Statistics
EPS (TTM)N/A
Shares Outstanding34,297,638
10 Day Avg. Volume18,904
30 Day Avg. Volume28,000
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.30
Price to Sales (P/S)0.51
P/FCF Ratio-4.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Modiin Pu Business Overview & Revenue Model
Company DescriptionModiin Energy-Limited Partnership engages in the exploration, development, and production of oil and gas assets in the United States and Israel. It holds interests in the Mountainview, GrapeVine, Cassini, and Shideler projects in California; NPB project in Colorado; and Shimshon in Israel. The company was incorporated in 1992 and is based in Tel Aviv-Yafo, Israel.
How the Company Makes MoneyModiin Pu generates revenue through multiple streams, primarily by commercializing its proprietary drug candidates and technologies. The company engages in partnerships with pharmaceutical firms for the co-development of therapeutics, which often includes licensing agreements that provide upfront payments and milestone payments tied to the achievement of specific development goals. Additionally, MDIN earns revenue from selling its drug delivery platforms to other biotech companies. The firm may also receive royalties from successful products that utilize its technologies, thereby creating a diverse revenue model that leverages both direct sales and collaborative ventures within the pharmaceutical industry.
Modiin Pu Financial Statement Overview
Summary
Mixed operating performance: solid gross (~47%) and positive EBIT/EBITDA margins, but TTM revenue declined (~-6.9%) and the company remains loss-making (net margin ~-30%). Leverage has risen sharply (debt/equity ~2.41) and free cash flow is still negative (~-5.2M), which pressures overall financial strength.
Income Statement
48
Neutral
TTM (Trailing-Twelve-Months) revenue declined to ~20.9M (down ~6.9%), continuing a choppy top-line trend after the 2024 annual decline. Profitability is mixed: gross margin remains solid (~47%), and operating profitability is positive (EBIT margin ~15%, EBITDA margin ~37%), but the company is still loss-making at the bottom line (net margin ~-30%), following a larger loss in 2024 and a profit in 2023. Overall, margins above the gross/operating line are respectable, but earnings volatility and persistent net losses weigh on the score.
Balance Sheet
35
Negative
Leverage has increased meaningfully: total debt rose to ~83.0M in TTM (Trailing-Twelve-Months) versus ~58.7M in 2024, pushing debt relative to equity to ~2.41 (up from ~1.49 in 2024 and ~1.30 in 2023). Equity is still positive (~34.5M TTM), but returns to shareholders are negative in TTM (return on equity ~-16.6%) and were also negative in 2024, indicating weakened earning power against a more leveraged capital structure. The balance sheet shows scale-up, but higher leverage and negative returns are key risks.
Cash Flow
42
Neutral
Cash generation from operations is positive in TTM (Trailing-Twelve-Months) at ~7.0M, but it is down versus 2024 (~10.3M). Free cash flow remains negative in TTM (~-5.2M), extending a multi-year pattern of cash burn despite some improvement versus several prior years. Operating cash flow covers only part of accounting losses in TTM (about ~0.81x), suggesting losses are not fully offset by operating cash generation; the continued negative free cash flow is the main weakness.
Breakdown
TTM
Dec 2024
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Income Statement
Total Revenue
20.93M
23.09M
27.03M
19.86M
17.64M
1.73M
Gross Profit
9.90M
11.94M
16.03M
13.86M
12.41M
628.00K
EBITDA
7.76M
9.10M
11.99M
9.54M
8.26M
-1.43M
Net Income
-6.25M
-9.45M
2.12M
-2.79M
6.56M
-6.02M
Balance Sheet
Total Assets
123.15M
107.23M
106.09M
80.44M
43.16M
13.68M
Cash, Cash Equivalents and Short-Term Investments
19.26M
2.16M
3.61M
1.63M
1.96M
1.33M
Total Debt
83.04M
58.73M
51.90M
31.18M
16.00M
0.00
Total Liabilities
88.69M
67.79M
66.15M
46.64M
20.25M
1.19M
Stockholders Equity
34.47M
39.44M
39.93M
33.79M
22.91M
12.48M
Cash Flow
Free Cash Flow
-5.25M
-2.88M
-18.94M
-23.81M
-15.52M
-1.29M
Operating Cash Flow
7.03M
10.34M
11.91M
11.69M
8.25M
-233.00K
Investing Cash Flow
-13.95M
-13.60M
-32.07M
-38.96M
-25.62M
-3.11M
Financing Cash Flow
14.30M
1.64M
21.99M
27.13M
18.12M
3.02M
Modiin Pu Technical Analysis
Technical Analysis Sentiment
Negative
Last Price67.70
Price Trends
50DMA
72.35
Positive
100DMA
89.45
Negative
200DMA
118.19
Negative
Market Momentum
MACD
1.02
Negative
RSI
50.17
Neutral
STOCH
48.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:MDIN, the sentiment is Negative. The current price of 67.7 is below the 20-day moving average (MA) of 72.63, below the 50-day MA of 72.35, and below the 200-day MA of 118.19, indicating a neutral trend. The MACD of 1.02 indicates Negative momentum. The RSI at 50.17 is Neutral, neither overbought nor oversold. The STOCH value of 48.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:MDIN.
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 28, 2026